{"id":783755,"date":"2023-09-13T09:49:28","date_gmt":"2023-09-13T13:49:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/"},"modified":"2023-09-13T09:49:28","modified_gmt":"2023-09-13T13:49:28","slug":"imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/","title":{"rendered":"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development<\/p>\n<p align=\"justify\">\n        <strong>LAWRENCEVILLE, N.J., Sept.  13, 2023  (GLOBE NEWSWIRE) &#8212; IMUNON,<\/strong><br \/>\n        <strong> Inc.<\/strong><br \/>\n        <strong> (Nasdaq:<\/strong><br \/>\n        <strong>IMNN)<\/strong><br \/>\n        <strong>,<\/strong> a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&amp;D Day event tomorrow, September 14<sup>th<\/sup> beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5EdfiV7sgzPMIznh37Rf5stFB9i4GyKcNwiPaeclMHfO8LMgnoIxbwNXCxUKzoXyhVM-Khr5MBdamMZ-mk4h05pVZl5QLKpzPsFYh5eib9VB8Oc4J9Nxk4AaThnRQpsRYFl1HRV8PZG0HMj3Ur_1kQ==\" rel=\"nofollow noopener\" target=\"_blank\">Scientific Presentations<\/a> section of IMUNON\u2019s website or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d2pfWw_aox6DPgvIiIdikWJHl_I_VaUBxHM6OgUkawefkefo-0qJPfov80nrAktcRnLLm3VJ-Li4hc4C9vjpj1twDR4OHd5OFGa3pP0Bq9sLchEhKUlwLUs9uZh1Ms_o\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Following management\u2019s presentations, a Q&amp;A session will be available via the chat function of the webcast.<\/p>\n<p align=\"justify\">\n        <strong>The Event\u2019s Speakers<\/strong>\n      <\/p>\n<p align=\"justify\">IMUNON presenters include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Dr. Corinne Le Goff, President and Chief Executive Officer<\/li>\n<li style=\"text-align:justify\">Khursheed Anwer, Ph.D., Executive Vice President and Chief Science Officer<\/li>\n<\/ul>\n<p align=\"justify\">Guest key opinion leader presenters include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Sallie Permar, M.D., Ph.D., Chair of the Department of Pediatrics at Weill Cornell Medicine and Pediatrician-in-Chief at New York-Presbyterian\/Weill Cornell Medical Center and New York-Presbyterian Komansky Children\u2019s Hospital. She is also Nancy C. Paduano Professor and Chair, Weill Cornell Medicine.<\/li>\n<li style=\"text-align:justify\">Patrick Ott, M.D., Ph.D., Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. He is also an attending physician in the Department of Medicine at Brigham and Women&#8217;s Hospital and is an Associate Professor at Harvard Medical School.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About IMUNON<\/strong>\n      <\/p>\n<p align=\"justify\">IMUNON is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas<sup>TM<\/sup>, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine<sup> TM<\/sup> is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The third modality, FixPlas<sup> TM<\/sup>, concerns the application of our DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, which is in the discovery phase, IndiPlas<sup> TM<\/sup>, will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines.<\/p>\n<p align=\"justify\">The Company\u2019s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical studies for the development of a COVID-19 booster vaccine: IMNN-101. The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma: IMNN-201. We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=41-mAOAErBwtVbput0ieyv7nqZkZ2ucNyu1TMouNt2ExwDcf4WwPMN_rrrwJwRjyzbhDDCXkE9a_UEqsh81HzQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.imunon.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>IMUNON<\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>LHA Investor Relations<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Jeffrey W. Church<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Kim Sutton Golodetz<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Executive Vice President, CFO<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">212-838-3777<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">and Corporate Secretary<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:Kgolodetz@lhai.com\" rel=\"nofollow noopener\" target=\"_blank\">Kgolodetz@lhai.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">609-482-2455<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:jchurch@imunon.com\" rel=\"nofollow noopener\" target=\"_blank\">jchurch@imunon.com<\/a>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\"># # #<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODdiYTNmNGYtYjM0ZC00NDdlLThhMzgtM2M2MjA5MTQzN2ZhLTUwMDA0OTc3Ng==\/tiny\/Imunon-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&amp;D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in the Scientific Presentations section of IMUNON\u2019s website or here. Following management\u2019s presentations, a Q&amp;A session will be available via the chat function of the webcast. The Event\u2019s Speakers IMUNON presenters include: Dr. Corinne Le Goff, President and Chief Executive Officer Khursheed Anwer, Ph.D., Executive Vice President &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-783755","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&amp;D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in the Scientific Presentations section of IMUNON\u2019s website or here. Following management\u2019s presentations, a Q&amp;A session will be available via the chat function of the webcast. The Event\u2019s Speakers IMUNON presenters include: Dr. Corinne Le Goff, President and Chief Executive Officer Khursheed Anwer, Ph.D., Executive Vice President &hellip; Continue reading &quot;IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-13T13:49:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET\",\"datePublished\":\"2023-09-13T13:49:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/\"},\"wordCount\":558,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/\",\"name\":\"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==\",\"datePublished\":\"2023-09-13T13:49:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/","og_locale":"en_US","og_type":"article","og_title":"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET - Market Newsdesk","og_description":"Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&amp;D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in the Scientific Presentations section of IMUNON\u2019s website or here. Following management\u2019s presentations, a Q&amp;A session will be available via the chat function of the webcast. The Event\u2019s Speakers IMUNON presenters include: Dr. Corinne Le Goff, President and Chief Executive Officer Khursheed Anwer, Ph.D., Executive Vice President &hellip; Continue reading \"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-13T13:49:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET","datePublished":"2023-09-13T13:49:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/"},"wordCount":558,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/","name":"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==","datePublished":"2023-09-13T13:49:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTEyNSM1ODExNDE1IzUwMDA0OTc3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-reminds-investors-of-its-virtual-rd-day-tomorrow-at-400-p-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMUNON Reminds Investors of its Virtual R&amp;D Day Tomorrow at 4:00 p.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=783755"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783755\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=783755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=783755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=783755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}